Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis - Wikidata - awgldk - TriplyDB

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

http://www.wikidata.org/entity/Q24802737

about

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis Year in review in Critical Care, 2003 and 2004: respirology and critical care.The significance of different formulations of aerosolized colistin.Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature review Inhaled Antibiotics for Gram-Negative Respiratory Infections Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin Colistin in the 21st century.A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema.A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa.Drug treatment for multidrug-resistant Acinetobacter baumannii infections.The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.Acinetobacter baumannii: emergence of a successful pathogen Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients.Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.Role of inhaled antibacterials in hospital-acquired and ventilator-associated pneumonia.Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation.Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.Year in review 2005: Critical Care--respirology: mechanical ventilation, infection, monitoring, and education.Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.Prognostic differences between VAP from Acinetobacter baumanii and VAP from other microorganisms.Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa Polymyxins revisited.Administration of antibiotics via the respiratory tract as monotherapy for pneumonia.Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii.Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia.New information about the polymyxin/colistin class of antibiotics.Treatment of Acinetobacter infections.Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance.Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development.Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update.Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia.Inhaled colistin for lower respiratory tract infections.Colistin: an update on the antibiotic of the 21st century.

P2860

Q21092897-A9160FB2-68DE-4A56-9081-8CAF0D0A62AA Q24802824-2E641E47-8B1A-466A-A5DB-999E3DD15AE8 Q24813226-C5B0648D-716D-4DEA-81CF-9EF5FAA81BD4 Q24817033-53C62C38-68DE-4BF3-8D78-0C7D6FA553A5 Q26751255-0015DB18-20AC-45CA-BA78-A9790D1C2321 Q26796605-7C6AAFB3-B7C8-4AC2-8563-0614D9F607DB Q28386160-A0267FCF-D0F1-467D-A77F-BCB2F9525965 Q30608976-B402CB7D-CF85-46E5-B8F1-5B56C855D4EE Q33798554-234C8C8F-C9EF-4DED-A2AD-E7305EFE810A Q33847509-FE60200B-569E-4CBD-8E8B-B1F654E801B3 Q33934859-A152EEC9-F340-4020-B807-49C2DBF5358F Q34074975-3ADB3D1A-1B35-4A40-880F-E4C0B87B4331 Q34601684-751DE0DF-4170-46E6-8283-1D17126393AB Q34652418-4D808228-8C81-4EA6-BB16-F8E64E71F4EB Q34795807-12BD3A3A-F328-41E6-AFF1-06ED569E0C47 Q35052517-1DD7D9AC-A3EB-4DCD-B785-33AD35B0DED5 Q35223347-37DA903A-DC23-44B2-845A-15B234B52C29 Q36095874-9E0B0AD1-F3DB-435A-97B8-B5F0BE4E626A Q36162380-BED9B68A-0353-46BF-97D0-25D05B7C7F2A Q36222127-B06FDBAE-22FB-4D0A-AA36-7D79321D50BE Q36268383-FA040BE3-45B7-42DD-84FC-D0EA73733AEB Q36281234-0A086129-6F4C-482F-9DB7-65A0AE2C9C54 Q36526019-37F3FF5D-2988-4405-B3E7-CB4863800B79 Q36870716-575D2F0B-6FA5-4EEA-8226-535C943A3ADE Q37058361-41CF12A8-EE82-424D-A614-B86E56082C53 Q37145741-CA30A31C-A134-4A75-A693-703E869F71A4 Q37215935-B45F5DA7-8762-4003-830D-A5BC8ED5C3DA Q37228727-8DE193F9-53A4-4070-A1AB-9EDBBB9F809F Q37418760-0C2ACCF3-B8F8-41D4-BFE1-D5E9C5ECE1F4 Q37583907-43CEC5C5-9CBC-4624-9186-A3D8E126F94C Q37636150-4D1D1445-5B23-4A35-BA21-8AA4725D32EA Q37704397-D3AD223F-1652-4C50-BFA1-7EAA06652B62 Q37760514-4B1950DA-B99A-4962-88BF-8589DA264241 Q37838126-AF28B6F2-CAE6-49AC-88C9-B5F30337F6D3 Q37869910-68E8E5B0-1C33-4F87-8CD6-01CA55020D70 Q37894693-8691FB0E-7808-4BDE-9ED7-0BCACF2CD459 Q37915360-76ABCCC9-976F-4A81-A57B-9F73270F3A93 Q37949636-28566975-E37B-4EDC-9CC2-D6EE1A99CFBA Q37983920-3765373B-6C0E-4F99-ABAC-E586D38F149F Q38048852-0BB423CE-6CB2-463F-8BA6-51D2162CC8CA

P2860

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

http://www.wikidata.org/entity/Q24802737

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Aerosolized colistin for the t ...... tients without cystic fibrosis

@ast

Aerosolized colistin for the t ...... tients without cystic fibrosis

@en

Aerosolized colistin for the t ...... tients without cystic fibrosis

@nl

type

label

Aerosolized colistin for the t ...... tients without cystic fibrosis

@ast

Aerosolized colistin for the t ...... tients without cystic fibrosis

@en

Aerosolized colistin for the t ...... tients without cystic fibrosis

@nl

prefLabel

Aerosolized colistin for the t ...... tients without cystic fibrosis

@ast

Aerosolized colistin for the t ...... tients without cystic fibrosis

@en

Aerosolized colistin for the t ...... tients without cystic fibrosis

@nl

P1433

Q24802737-765F4C69-F59E-466D-A117-A6BCBF5329A6

P1476

Q24802737-A408015E-B755-4E95-B868-6DF870C01D71

P2093

Q24802737-2E97C8B8-AEFF-43EC-B667-D233BE591411

Q24802737-826A1B08-E754-4C8E-A636-A0139C0FF402

Q24802737-870D375A-0BD1-48E5-BF86-EA7D3077F493

Q24802737-CA00972A-9209-410C-BA0A-04A3107DC4FD

P2860

Q24802737-031F1CEA-5F86-401B-8B49-70D4D8CB52EF

Q24802737-12EE1B14-9FEB-484E-96F8-10FFD4D9AC60

Q24802737-254433B2-D233-44EB-8422-09DD364D7258

Q24802737-2CD33BDF-94BD-4C5A-B6C7-58C1899F3072

Q24802737-3A161B93-6BFB-4C35-8736-770AA8DE5EFA

Q24802737-57F8F158-57E0-48B5-BEEB-A4E489977E69

Q24802737-5F8A4894-6922-4EF5-824A-2FD853523139

Q24802737-615C6564-7BD6-44DD-A7BC-ED90BD55BBA2

Q24802737-639A8917-0ADF-47B3-8A61-C5BB9A7CBBA8

Q24802737-64880278-F5F2-466A-A859-BB5C4297BFFD

P2888

Q24802737-38836EE0-6F5B-4BC6-9898-D20A72182476

P304

Q24802737-474696D6-A4A7-47FA-AF0D-123609B4873E

P31

Q24802737-626062A7-23AF-478F-8947-D55FF31DE0A4

P356

Q24802737-DABB78EC-820C-4B3A-AFF5-794171CB6CD5

P407

Q24802737-01BBC0DC-BB0D-4342-A505-335E34DF4B49

P433

Q24802737-795FCD99-5F3A-4EB9-9D1F-99DDEBBAA4E6

P478

Q24802737-E57015A6-BE4D-45BB-A354-324C8261167A

P50

Q24802737-5E08CBBF-75E2-47DE-A75F-FB426F587830

Q24802737-82EB2117-E839-4AD8-B349-9E02E97C2470

P577

Q24802737-1E66C3F8-B452-49A5-89AF-4D46CF4763CA

P5875

Q24802737-35B026AE-F3A3-4CA3-ACD3-5CAF2D0BD880

P6179

Q24802737-2076864F-FF0E-442D-9518-5E6E4D6BE44D

P698

Q24802737-D8C84795-BCA3-4854-8417-961A935D6F98

P921

Q24802737-0F7437A7-CAAC-4599-B170-02A8161EBFF8

Q24802737-108B3A8F-55DB-42F6-B69E-BA7B6A0F65BE

Q24802737-33737112-4F81-4DC3-B720-0C838EA25E1E

Q24802737-C6844DAF-C1F7-4363-879F-33F0616DAB42

Q24802737-E18ADAEF-D5B2-46A3-A981-8206BC971AE0

Q24802737-E4457CF8-7AF7-44C3-835E-B48C8CD1D69F

Q24802737-F6BBB933-5DC4-41CA-8218-179AD6B2FD85

P932

Q24802737-B0014E7C-A6E9-417F-B318-D7BF259A51F5

P356

P1433

P1476

Aerosolized colistin for the t ...... tients without cystic fibrosis

@en

P2093

Anastasios M Kapaskelis

http://www.w3.org/2001/XMLSchema#string

Kostas Rellos

http://www.w3.org/2001/XMLSchema#string

Sofia K Kasiakou

http://www.w3.org/2001/XMLSchema#string

Zefi Mastora

http://www.w3.org/2001/XMLSchema#string

P2860

Ventilator-associated pneumonia

The clinical use of colistin in patients with cystic fibrosis.

Nebulized colistin causes chest tightness in adults with cystic fibrosis.

Nebulized colistin (polymyxin E) for AIDS-associated Pseudomonas aeruginosa pneumonia.

Ultra-sonic nebulizers as a potential source of methicillin-resistant Staphylococcus aureus causing an outbreak in a university tertiary care hospital.

Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin.

Aerosol polymyxin and pneumonia in seriously ill patients.

Endotracheal antibiotics for the prevention of tracheobronchial infections in tracheotomized unconscious patients. A comparative study of gentamicin and aminosidin-polymyxin B combination.

Bacterial contamination potential of sterile, prefilled humidifiers and nebulizer reservoirs.

Bronchoconstriction following nebulised colistin in cystic fibrosis.

P2888

P304

R53-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC3020

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Argyris S. Michalopoulos

Matthew E. Falagas

P577

2005-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8038680

http://www.w3.org/2001/XMLSchema#string

P6179

1044277255

http://www.w3.org/2001/XMLSchema#string

P698

15693967

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

Gram-negative bacteria

multiple drug resistance

P932

1065114

http://www.w3.org/2001/XMLSchema#string